Format

Send to

Choose Destination
Cell Metab. 2012 Feb 8;15(2):150-6. doi: 10.1016/j.cmet.2012.01.002.

Challenges and opportunities of defining clinical leptin resistance.

Author information

1
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA. mgmyers@umich.edu

Abstract

The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.

PMID:
22326217
PMCID:
PMC3281561
DOI:
10.1016/j.cmet.2012.01.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center